AbbVie tops quarterly expectations as newer immunology drugs offset Humira decline

AbbVie posted Q1 adjusted EPS of $2.65 on revenue of $15.0 billion, both ahead of expectations ($2.59 and $14.72 billion). Skyrizi sales rose 30.9% to $4.48 billion and Rinvoq sales increased 23.3% to $2.12 billion, helping offset Humira’s 38.6% decline to $688 million. The company raised full-year adjusted EPS guidance to $14.08-$14.28 from $13.96-$14.16, though the outlook includes a 41-cent per share hit from acquired R&D and milestone expenses.

Analysis

The core read-through is not just that ABBV is executing, but that it is extending the life of its post-Humira cash engine faster than the market has modeled. That matters because the next leg of the equity story is less about top-line growth and more about preserving peak-margin reinvestment capacity: every incremental point of confidence in Skyrizi/Rinvoq durability lowers the probability of a valuation reset when Humira erosion finally bottoms. The neuroscience outperformance is especially important because it reduces single-portfolio dependency and gives ABBV a second internal source of compounding that can absorb policy noise.

The bigger second-order effect is competitive: strong execution here raises the hurdle for smaller immunology players trying to justify premium multiples on growth alone. If ABBV keeps converting share into durable revenue at this pace, pricing pressure will likely migrate to the periphery of the category, where biosimilar and next-gen entrants have weaker reimbursement leverage and less channel power. That creates a medium-term squeeze for peers that rely on the market assuming a clean handoff from legacy franchises to new launches.

The updated earnings guide is subtly more important than the beat. Management is signaling it can absorb in-process R&D drag while still lifting forward EPS, which usually supports a multiple floor because it implies the capital allocation machine is intact. The main risk is that the market extrapolates near-term momentum too far: if immunology growth normalizes over the next 2-4 quarters or if policy rhetoric turns back toward drug pricing, the stock could give back a meaningful portion of the rerating. But for now, the setup favors continued fundamental revisions over a re-rating reversal.

Key Decisions for Investors

• Add to ABBV on 1-3 month dips; the setup favors estimate revisions over valuation compression as long as Skyrizi/Rinvoq growth stays above the low-20% range. Target a move toward the next earnings print with upside driven by sustained EPS guidance support.
• Buy ABBV call spreads 2-4 months out to express continued multiple support without paying full vol; risk/reward is attractive if the market keeps rewarding durability in the post-Humira transition.
• Long ABBV / short a basket of smaller immunology and autoimmune peers with weaker diversified cash flow, to express the view that incumbent scale and reimbursement power will outlast pipeline excitement.
• Trim or hedge ABBV if immunology growth decelerates sharply next quarter or if U.S. drug-pricing headlines re-accelerate; those are the two main catalysts that could compress the multiple over a 1-2 quarter horizon.
• Watch for any post-earnings analyst revisions to 2026 EPS and FCF; if upward revisions are broad-based, add on strength rather than waiting for pullbacks, because the market may be underpricing the durability of the non-Humira earnings base.